COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 801

Article download: 198

Indian Journal of Pharmacy and Pharmacology

“Effect of Rosiglitazone alone and in combination with Sulfasalazine in experimentally induced inflammatory bowel disease in rats”

Full Text PDF Share on Facebook Share on Twitter

Author Details : Shivashankar P, Purushotham K, Mangala Lahkar

Volume : 3, Issue : 3, Year : 2016

Article Page : 108-114

Suggest article by email


Background: Inflammatory bowel disease (IBD) is an idiopathic, chronic inflammatory condition, which affects the gastrointestinal tract and has no curative treatment. The present study aimed to investigate the effect of different doses of Rosiglitazone alone and in combination with sulfasalazine in AA (acetic acid)-induced inflammatory bowel disease (IBD) in rats.
Methods: A total of 36 animals were included in the study. Animals were divided into five groups (n = 6): group I - control (normal saline), group II-AA+ normal saline, group III-Sulfasalazine(360mg/kg) +AA, group IV A - Rosiglitazone (1 mg/kg), group IV B- Rosiglitazone 5 mg/kg + AA, group V - Rosiglitazone 5 mg/kg + Sulfasalazine (360 mg/kg) +AA. Group IV was divided into two subgroups, namely IVA and IVB, on the basis of different doses of Rosiglitazone used. After completion of one week of treatment, rats were sacrificed under ether anesthesia for assessment of intestinal inflammation using parameters namely colon weight change, macroscopic and histopathological evaluation.
Results: There was a decrease in colonic weight, macroscopic scores and microscopic scores in groups treated with Rosiglitazone at a dose of 5 mg/kg i.e. high dose given alone and in combination with sulfasalazine .Combination treatment was more effective when compared to single drug treatment.
Conclusion: The present study indicates the efficacy of Rosiglitazone in Acetic acid-induced IBD. The effects are more pronounced at higher dose i.e., 5 mg/kg. Combination of Rosiglitazone and Sulfasalazine has shown greater efficacy than single drug treatment.

Inflammatory bowel disease, Rosiglitazone, Colon weight change, Macroscopic evaluation, Histopathological evaluation

How to cite : Shivashankar P, Purushotham K, Lahkar M, “Effect of Rosiglitazone alone and in combination with Sulfasalazine in experimentally induced inflammatory bowel disease in rats”. Indian J Pharm Pharmacol 2016;3(3):108-114

Copyright © 2016 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (